VNDA FY2025 EPS Estimate Lowered by Cantor Fitzgerald

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Cantor Fitzgerald cut their FY2025 earnings estimates for Vanda Pharmaceuticals in a research report issued on Thursday, May 8th. Cantor Fitzgerald analyst C. Duncan now anticipates that the biopharmaceutical company will post earnings of ($1.55) per share for the year, down from their previous forecast of ($1.26). The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($1.12) per share.

A number of other research analysts have also recently commented on the stock. StockNews.com began coverage on shares of Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They set a “hold” rating on the stock. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 7th.

Vanda Pharmaceuticals Trading Down 6.2%

NASDAQ VNDA opened at $3.96 on Monday. The company’s fifty day simple moving average is $4.52 and its 200-day simple moving average is $4.65. Vanda Pharmaceuticals has a 52 week low of $3.85 and a 52 week high of $6.75. The stock has a market cap of $233.38 million, a P/E ratio of -12.38 and a beta of 0.69.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.05. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The company had revenue of $50.04 million during the quarter, compared to the consensus estimate of $45.13 million.

Institutional Trading of Vanda Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in VNDA. Schonfeld Strategic Advisors LLC acquired a new stake in Vanda Pharmaceuticals in the fourth quarter valued at $1,296,000. Millennium Management LLC raised its holdings in Vanda Pharmaceuticals by 67.4% in the fourth quarter. Millennium Management LLC now owns 668,693 shares of the biopharmaceutical company’s stock valued at $3,203,000 after acquiring an additional 269,183 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in Vanda Pharmaceuticals in the fourth quarter valued at $1,221,000. Dimensional Fund Advisors LP raised its holdings in shares of Vanda Pharmaceuticals by 10.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,488,519 shares of the biopharmaceutical company’s stock worth $11,920,000 after purchasing an additional 227,428 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Vanda Pharmaceuticals during the first quarter worth $875,000. 88.14% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Vanda Pharmaceuticals

In related news, CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the business’s stock in a transaction that occurred on Friday, February 28th. The shares were purchased at an average cost of $4.76 per share, with a total value of $47,600.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,361,730 shares of the company’s stock, valued at approximately $11,241,834.80. The trade was a 0.43% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have purchased 32,000 shares of company stock valued at $151,180 over the last ninety days. Corporate insiders own 10.00% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.